pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,291 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT966Endpoints741BioPharma Dive283BioSpace181Fierce Biotech172onclive165globenewswire health73raps
therapy area
allOncology5599Rare Disease1245Cardiology1051Hematology933Immunology917Vaccines811Pulmonology
  • EU releases AI Act transparency guidelines, affecting health-tech developers
    The European Commission has published new guidelines to help providers and users of artificial intelligence systems meet the transparency obligations set out in the EU AI Act. The document explain…
    raps · 24d agoRegulatoryNeutral↗ source
  • Right-wing groups intensify campaign to limit abortion pills amid ongoing health news
    Advocates on the political right are renewing efforts to restrict access to medication abortions, according to the latest Morning Rounds newsletter. The piece notes that the campaign is gaining mom…
    STAT · 24d agoNegative↗ source
← prev
page 27 of 92
next →
63
fda recalls41
fda medwatch30
fda press25
776
Psychiatry & CNS688
Ophthalmology343
Endocrinology & Metabolism338
Pain335
Infectious Disease323
  • Opinion warns post-pandemic polarization may lock in false lessons from Covid response
    The authors, Marc Lipsitch and Sara Cody, argue that the public and policymakers are drawing misleading conclusions from the Covid-19 pandemic. They point out that early nonpharmaceutical interven…
    STAT · 24d agoNegative↗ source
  • Tempus AI to buy cancer test maker Personalis for $1.5 billion
    Tempus AI announced it will acquire Personalis, a California-based company that offers a molecular residual disease test for cancer, in a transaction valued at $1.5 billion. The deal, priced at $1…
    BioPharma Dive · 25d agoDealPositive↗ source
  • Samsung Biologics to acquire Swiss CDMO PolyPeptide for $1.8 billion, entering peptide API market
    Samsung Biologics announced a plan to purchase Swiss contract development and manufacturing organization PolyPeptide for $1.8 billion in cash. The acquisition will extend Samsung Biologics' manufa…
    Endpoints · 25d agoDealPositive↗ source
  • Medicare proposes cuts to hospital payments for drugs and imaging under new outpatient rule
    Medicare's Centers for Medicare & Medicaid Services released a proposed rule that would lower the amounts hospitals receive for certain prescription drugs and imaging services provided to Medicare…
    STAT · 25d agoRegulatoryNegative↗ source
  • UK regulator reports rise in drug approvals and new AI healthcare regulations
    The UK's Medicines and Healthcare products Regulatory Agency (MHRA) released its 2025-2026 annual report to Parliament. The agency highlighted that it approved more new medicines in the past year…
    raps · 25d agoRegulatoryPositive↗ source
  • Study finds China approved more cancer drugs than US between 2020-2025, but US led in first-in-class and speed
    A new analysis published in Health Affairs compares oncology drug approvals by China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) from 2020 thro…
    raps · 25d agoRegulatoryNeutral↗ source
  • UK regulator reports rise in drug approvals and steps to regulate AI in healthcare
    The Medicines and Healthcare products Regulatory Agency (MHRA) presented its 2025-2026 annual report to Parliament, highlighting a higher number of new drug approvals compared with the previous yea…
    raps · 25d agoRegulatoryPositive↗ source
  • Tempus AI to acquire cancer test maker Personalis for $1.5 billion
    Tempus AI announced it will buy Personalis, a Fremont-based company that offers a molecular residual disease test for cancer, in a deal valued at $1.5 billion. The acquisition is expected to expan…
    BioPharma Dive · 25d agoDealPositive↗ source
  • Latigo Biotherapeutics Announces Plans for Nasdaq IPO to Fund Non-Opioid Pain Drug Development
    Latigo Biotherapeutics, a Westlake BioPartners spin‑out founded in 2018, said it will seek a Nasdaq listing under the ticker LTGO. The company develops non‑opioid analgesics that block sodium ion…
    BioPharma Dive · 25d agoDealPositive↗ source
  • Anthropic ramps up biopharma push with Nobel hires and M&A plans
    Anthropic, known for its artificial‑intelligence models, is expanding its focus to life sciences after a detailed internal memo outlined the move. The memo, released in late 2024, named biology an…
    Endpoints · 25d agoPositive↗ source
  • Former staff allege LifeMD prioritized GLP-1 prescription volume over patient safety
    Novo Nordisk lists telehealth firm LifeMD on its website as a provider that offers legitimate medicine sourcing and patient support for individuals seeking GLP-1 drugs such as Ozempic and Wegovy.…
    STAT · 25d agoNegative↗ source
  • UK biotech venture capital funding hits record high in Q2 2026, surpassing any full year since 2022
    UK biotech companies secured more venture capital in the second quarter of 2026 than they did in any full calendar year since 2022. The surge reflects a broader fundraising revival, with investors…
    Endpoints · 25d agoDealPositive↗ source
  • Bristol Myers Squibb partners with Nvidia to build pharma's most advanced AI supercomputer
    Bristol Myers Squibb announced it will construct what it calls the most advanced and energy-efficient AI supercomputer system in the biopharma sector. The project will be carried out in partnershi…
    Endpoints · 25d agoDealPositive↗ source
  • Bristol Myers Squibb announces construction of pharma’s largest NVIDIA AI supercomputer
    Bristol Myers Squibb (BMS) said it is building what it calls the largest AI supercomputer in the life‑science sector, marking the third such claim by a drugmaker in nine months. The effort expands…
    STAT · 25d agoPositive↗ source
  • Former LifeMD staff say company pushed rapid GLP-1 prescriptions at expense of patient safety
    Former employees of telehealth firm LifeMD allege the company encouraged clinicians to see more patients and issue weight‑loss drug prescriptions quickly, with limited screening or follow‑up. Five…
    STAT · 25d agoNegative↗ source
  • Iowa audit finds PBM kept over $100 million by inflating Medicaid drug costs
    A recent audit of Iowa's Medicaid program uncovered that a major pharmacy benefit manager used complex claim handling methods that led to higher costs for the state. The review of records from 201…
    STAT · 25d agoRegulatoryNegative↗ source
  • UnitedHealth outlines AI rollout as quarterly results beat expectations
    UnitedHealth Group, a major health insurer, announced a substantial investment in artificial intelligence earlier this year. The company recently detailed how the technology is being integrated in…
    Endpoints · 25d agoPositive↗ source
  • House lawmakers support US trade panel's probe into China's biotech sector and pricing practices
    At least ten members of the U.S. House of Representatives have voiced support for a trade investigation targeting China’s biotechnology industry. The investigation, led by a U.S. trade panel, will…
    Endpoints · 25d agoRegulatoryNeutral↗ source
  • J&J and AbbVie also considered AtaiBeckley before Lilly’s $2.8 B acquisition
    Johnson & Johnson and AbbVie were reported to have evaluated AtaiBeckley as a potential target in the psychedelic market. The companies did not submit an offer before Eli Lilly closed its $2.8 bil…
    Endpoints · 25d agoDealNeutral↗ source
  • Bristol Myers teams with Nvidia to launch large AI data center as Samsung Biologics bids $1.8 bn for Swiss peptide maker
    Bristol Myers Squibb announced expansion of its partnership with Nvidia, deploying two AI systems to create a powerful AI factory for life‑science research, aiming to tackle larger problems without…
    BioPharma Dive · 25d agoDealNeutral↗ source
  • Scribe targets $96 million from Nasdaq IPO as Scholar Rock awaits site classification for apitegromab
    Scribe, a gene-editing biotech, announced plans for a Nasdaq initial public offering that could raise roughly $96 million. The company said it would price the shares at $14 each, which is the midp…
    Endpoints · 25d agoDealNeutral↗ source
  • HHS vaccine committee receives new charter amid broader health policy updates
    The U.S. Health and Human Services vaccine advisory panel has been granted a new charter, a change that was noted quietly in a recent health newsletter. The same briefing highlighted other policy…
    STAT · 25d agoRegulatoryNeutral↗ source
  • Pandemics Should Be Treated as National Security Threats, Experts Argue
    In an opinion piece, David Blumenthal and James A. Morone argue that pandemics should be classified and addressed as national security threats rather than solely health-care challenges. They note…
    STAT · 25d agoPositive↗ source